LifeMD vs Teladoc Health
LFMD and TDOC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFMD and TDOC compare
Teladoc Health is the larger company, worth 15 times as much as LifeMD ($1.6B against $106M).
LifeMD grew revenue faster over the last twelve months (23.6% versus −2.4% for Teladoc Health).
LifeMD keeps more of each dollar of sales as profit, with a net margin of 0.21% compared with −6.3% at Teladoc Health.
LifeMD scores higher on the StockData Score (13 against 4 for Teladoc Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFMD | TDOC |
|---|---|---|
| Size and price | ||
| Market cap | $106M | $1.6B |
| Share price | $2.19 | $8.80 |
| Change, 1 year | −56.7% | 17.8% |
| Change, 5 years | −51.7% | −92.5% |
| Beta (5Y) | 1.73 | 1.97 |
| Employees | 389 | 5,600 |
| StockData Score | ||
| Total score | 13 (better) | 4 |
| Valuation score | 3 | 3 |
| Growth score | 3 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.6× (better) | 0.6× |
| P/B | – | 1.2× |
| P/FCF | – | 6.1× |
| FCF yield | −10.6% | 16.3% (better) |
| Fair value | $2.91 | $13.40 |
| Margin of safety | 24.6% | 34.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 23.6% (better) | −2.4% |
| Revenue growth, 5Y average | 39.1% (better) | 18.3% |
| Profitability | ||
| Gross margin | 86.5% (better) | 68.6% |
| Operating margin | −11.0% | −6.6% (better) |
| Net margin | 0.21% (better) | −6.3% |
| FCF margin | −5.9% | 10.6% (better) |
| Return on equity | 109% (better) | −11.5% |
| Return on invested capital | – | −23.2% |
| Financial health | ||
| Interest coverage | – | −8.0× |
| Current ratio | 0.80 | 0.87 (better) |
| Altman Z-score | −2.87 (better) | −7.09 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Payout ratio | 776% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 44.9% | 83.6% |
| Held by insiders | 18.2% | 0.71% |
| Insider net buying, 12 months | −$54.1K (better) | −$2.7M |
| Short interest, % of float | – | 17.8% |
Go deeper
- LFMD stock overview
- LFMD income statement
- LFMD valuation and score
- TDOC stock overview
- TDOC income statement
- TDOC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.